Erin Michos

Lipids Update 2022: Cardiovascular Risk Reduction and New Medications on the Horizon with Erin Michos, MDShow description: Ready to take the next step in management of your patient with hyperlipidemia? Dr. Erin Michos (@erinmichos) returns to give us a lesson in Advanced Lipidology. She updates us on what new medications we can use for those difficult to treat lipids and what medications are on the horizon.Unfortunately, this episode will not be available for CME. You can claim free CME for other episodes at curbsiders.vcuhealth.org!Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | askcurbsiders@gmail.com | Free CME!Show Segments Intro, Getting to know Dr. Erin Michos, Pick of the Week Patient Case, Digging into ASCVD Risk  Coronary artery calcium scoring - why it’s important What are “Risk Enhancing Factors”? Biomarker testing, what is the significance of Lip a and how can we use it to drive management? Introduction to PCSK9 inhibitors More than just statins - other LDL-lowering medications siRNAs, ASOs - Pelacarsen and more Apollo Trial regarding Pelacarsen Importance of Family History What to do if maxed out on a statin or statin intolerance - Ezetimibe, PCSK9 inhibitors, MAB therapies, and more Bempedoic Acid discussion Medication side effects Homozygous FH - approach to treatment, ANGPTL3 inhibitors Triglycerides discussion, icosapent ethyl, the REDUCE-IT trial Wrap-up and Take home points, Outtro Credits Producer and written by: Christopher Chiu MD, FACP, FAAP Show Notes: James Antaki MD Infographic: Edison Jyang Cover Art: Kate Grant MBChB, DipGUMed Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Associate Editor: Leah Witt MD Showrunner: Matthew Watto MD, FACP Technical Production: PodPaste Guest: Erin Michos MD, MHS Sponsor: Birch LivingBirch is giving $400 off all mattresses and 2 free eco-rest pillows at BirchLiving.com/curb. Full transcript HERE

Peter Toth, preventive cardiology leader with PCSK9 and LDL expertise, and Erin Michos, cardiovascular prevention clinician-scientist, discuss nonstatin therapies and practical implementation. They cover PCSK9 inhibitors vs apheresis, inclisiran and bempedoic acid, managing triglycerides and lipoprotein(a). They also tackle access barriers and safety of very low LDL levels.